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Objective: Our objective was to evaluate the published literature and reach a consensus on the
treatment of patients with ACTH-dependent Cushing’s syndrome, because there is no recent con-
sensus on the management of this rare disorder.
Participants: Thirty-two leading endocrinologists, clinicians, and neurosurgeons with specific ex-
pertise in the management of ACTH-dependent Cushing’s syndrome representing nine countries
were chosen to address 1) criteria for cure and remission of this disorder, 2) surgical treatment of
Cushing’s disease, 3) therapeutic options in the event of persistent disease after transsphenoidal
surgery, 4) medical therapy of Cushing’s disease, and 5) management of ectopic ACTH syndrome,
Nelson’s syndrome, and special patient populations.
Evidence: Participants presented published scientific data, which formed the basis of the recom-
mendations. Opinion shared by amajority of experts was usedwhere strong evidencewas lacking.
Consensus Process: Participants met for 2 d, during which there were four chaired sessions of
presentations, followed by general discussion where a consensus was reached. The consensus
statement was prepared by a steering committee and was then reviewed by all authors, with
suggestions incorporated if agreed upon by the majority.
Conclusions: ACTH-dependent Cushing’s syndrome is a heterogeneous disorder requiring a mul-
tidisciplinary and individualized approach to patient management. Generally, the treatment of
choice for ACTH-dependent Cushing’s syndrome is curative surgery with selective pituitary or
ectopic corticotroph tumor resection. Second-line treatments include more radical surgery, radi-
ation therapy (forCushing’s disease),medical therapy, andbilateral adrenalectomy.Becauseof the
significant morbidity of Cushing’s syndrome, early diagnosis and prompt therapy are warranted.
(J Clin Endocrinol Metab 93: 2454–2462, 2008)
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Endogenous Cushing’s syndrome is an endocrine diseasecaused by excessive secretion of ACTH in approximately
80% of cases, usually by a pituitary corticotroph adenoma
(Cushing’s disease), less often by an extrapituitary tumor (ec-
topic ACTH syndrome), and very rarely by an ectopic CRH-
secreting tumor. About 20% of patients have ACTH-indepen-
dent Cushing’s syndrome, i.e. excess cortisol secretion by
unilateral adrenocortical tumors or by bilateral adrenal hyper-
plasia or dysplasia (1).
In ACTH-dependent Cushing’s syndrome, elevated cortico-
troph tumor-derived ACTH secretion results in excess adrenal
gland cortisol secretion. The normal cortisol feedback mecha-
nism of the hypothalamo-pituitary-adrenal (HPA) axis is dis-
turbed, with loss of circadian rhythm and excess cortisol pro-
duction, resulting in hypercortisolism (2). Features of
hypercortisolism include weight gain, severe fatigue and muscle
weakness, high blood pressure, depression, cognitive impair-
ment, purplish skin striae, easy bruising, hyperpigmentation,
loss of libido, diabetes, hirsutism, acne, andmenstrual disorders
(1–5). In adults, muscular atrophy and purple striae can be im-
portant diagnostic features, whereas growth retardation is often
present in children. The diagnosis ofCushing’s syndrome is com-
plicated by the nonspecificity and high prevalence of clinical
symptoms in patientswithout the disorder and involves a variety
of biochemical tests of variable sensitivity and specificity. Effi-
cient screening and confirmatory procedures are therefore es-
sential before considering therapy. Treatment decisions should
be weighed carefully in patients with only mild or intermittent
hypercortisolism, because the benefits of surgery have not been
established definitively in this population.
In 2003, a consensus statement was published on the diag-
nosis and complications of Cushing’s syndrome (1). In April
2007, a workshop was held in Budapest, Hungary, to reach a
consensus on the treatment of ACTH-dependent Cushing’s syn-
drome. Participants included leading endocrinologists, clini-
cians, and neurosurgeons with specific expertise in the manage-
ment of ACTH-dependent Cushing’s syndrome, and the
workshop was endorsed by the European Neuroendocrine As-
sociation and The Pituitary Society. This paper is a summary of
the consensus reached on the treatment of ACTH-dependent
Cushing’s syndrome.
Part I: Criteria for Cure and Remission of
ACTH-Dependent Cushing’s Syndrome
Thegoals of treatment inACTH-dependentCushing’s syndrome
include the reversal of clinical features, the normalization of bio-
chemical changes with minimal morbidity, and long-term con-
trol without recurrence.
In general, the initial treatmentof choice forCushing’s disease
is selective pituitary adenomectomy by a surgeon with extensive
demonstrated experience in pituitary surgery. Tumor resection
leads to corticosteroid deficiency because the remaining normal
corticotroph cells have been suppressed by longstanding hyper-
cortisolism. As a result, hypocortisolism provides an index of
surgical success. However, patients with minimal preoperative
hypercortisolism, because of medical treatment or mild disease,
may be eucortisolemic and not require additional therapy. Thus,
the decision to treat a patientwith cortisol-loweringmedications
before surgery should be undertakenwith the realization that the
ability to assess curemay be compromised.Glucocorticoidwith-
drawal symptoms (e.g. fatigue, nausea, and joint aches) should
be anticipated in all patients; hypocortisolism and symptoms are
managedwithphysiological glucocorticoid therapyuntil the axis
recovers. Some patients with severe withdrawal symptoms re-
quire transient treatment with supraphysiological doses of glu-
cocorticoids (see below: Postoperative treatment of secondary
adrenal insufficiency).
We recommend assessment of remission by measurement of
morning serum cortisol during the first postoperative week, ei-
ther by withholding treatment with glucocorticoids or by using
low doses of dexamethasone (i.e. below the standard low-dose
test amount). If glucocorticoid treatment is withheld, it is essen-
tial that the patient be monitored closely for signs of hypoadren-
alism, preferably in-hospital; in centers where patients are rou-
tinely discharged to homewithin 36 h, this approachmay not be
feasible. Because glucocorticoids may suppress any remaining
tumor tissue and mask persistent disease, their use should be
avoided, or the dosage minimized, when cure is assessed.
The literature suggests that persistent postoperative morning
serum cortisol levels of less than 2 g/dl (50 nmol/liter) are
associated with remission and a low recurrence rate of approx-
imately 10% at 10 yr (6–14). A persistent serum cortisol level
above 5 g/dl (140 nmol/liter) for up to 6 wk requires further
evaluation. If persistent hypercortisolism is excluded, the recur-
rence rate is higher in these patients than in those with lower
values.When serum cortisol levels are between 2 and 5g/dl, the
patient can be considered in remission and can be observedwith-
out additional treatment for Cushing’s disease, as the recurrence
rate appears tobenogreater than that seen inpatientswith serum
cortisol levels less than 2 g/dl (6–14). Occasionally the serum
cortisol level falls more gradually, possibly reflecting transient
adrenal autonomy, and it is important to ensure that the cortisol
level has reached a nadir before considering further therapy.
Measurement of urinary free cortisol (UFC) can provide addi-
tional useful information when the serum cortisol level is equiv-
ocal. UFC values below 20 g/24 h (55 nmol/24 h) suggest re-
mission, whereas values in the normal range (20–100 g/24 h;
55–276 nmol/24 h) are equivocal. Values above the normal
range indicate persistent tumor.
Part II: Surgical Treatment of Cushing’s
Disease
Transsphenoidal pituitary resection: adenomectomy vs.
hypophysectomy
Cushing’s disease is caused by a discrete ACTH-secreting tu-
mor in themajority of cases (1); diffuse corticotroph hyperplasia
is rarely encountered. As a result, optimal treatment is surgical
resection by selective adenomectomy, performed by an experi-
enced surgeon, as long as the tumor can be identified. Careful
sectioning through the pituitary gland may be required to locate
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the tumor, because some tumors have an identifiable pseudo-
capsule, whereas others do not exhibit a discrete border between
the tumor and normal pituitary tissue. If the tumor was patho-
logically identified at initial surgery, the probability of subse-
quent successful resection is higher than if no tumor was found
initially. Remission rates in patients with a microadenoma un-
dergoing selective adenomectomyby an expert pituitary surgeon
are in the range of 65–90%. The recurrence rate in these patients
is 5–10%at5yr and10–20%at10yr (6, 11, 15–22),with young
age (25 yr or younger) being a significant risk factor for relapse
(22). Surgical success rates are lower in patients harboring mac-
roadenomas and in patients with tumors that have invaded the
dura (23). In patients with a macroadenoma, remission rates are
lower (65% in most series), and not only are recurrence rates
higher (12–45%)but recurrence alsooccurs sooner than in those
with a microadenoma (mean of 16 vs. 49 months) (21, 24, 25).
Transsphenoidal microsurgery is still the most widely used tech-
nique, and because there are limited data available on outcome
in entirely endoscopic operations, a comparison on outcome be-
tween microscopic and endoscopic pituitary surgery cannot be
made.
Favorable prognostic factors associated with successful ad-
enomectomy include detection of the microadenoma by mag-
netic resonance imaging (MRI), a well-defined tumor that is not
invading either the basal dura or cavernous sinus, histological
confirmation of an ACTH-secreting tumor, low postoperative
serum cortisol levels, and long-lasting adrenal insufficiency (6,
11, 15–20, 22, 26, 27).
For patients in whom a discrete microadenoma cannot be
located by sellar exploration, total or partial (central core or
hemi-) hypophysectomy may be indicated. However, total or
partial hypophysectomy induces remission less often (approxi-
mately 70% of patients) than selective tumor resection (11, 19,
26, 28, 29) and is associated with a higher rate of complications
and hypopituitarism than selective adenomectomy.
Postsurgical recurrence of Cushing’s disease may be higher
than that associated with other types of pituitary tumors, but
more data are needed to establish this observation.
Part III: Persistent Disease after
Transsphenoidal Surgery
The criteria for cure after transsphenoidal surgery are discussed
in Part I: Criteria for Cure and Remission of ACTH-dependent
Cushing’s Syndrome. In the event of failure after initial pituitary
surgery or relapse after a period of remission, a choice of second-
line therapeutic options needs to be discussed with the patient,
including repeat pituitary surgery, radiotherapy, or bilateral
adrenalectomy.
Pituitary surgery for persistent or recurrent disease
Repeat pituitary surgerymaybe undertaken if disease persists
after initial surgery, although there is an overall lower rate of
success than that seen after the first operation (30–32). It has
been shown to be efficacious in approximately two thirds (50–
70%) of patients in a limited number of specialized centers (18,
30–32), although remission rates are higher if an adenoma is
located. However, reoperation carries a significant risk of pitu-
itary insufficiency, particularly in patients undergoing hypoph-
ysectomy vs. selective adenomectomy (50 vs. 5%) (31). Im-
proved success rates are achieved in patients with radiologically
detectable tumors.
The ideal time for repeat transsphenoidal surgery for residual
disease is as soon as active, persistent disease is evident. A delay
of 4–6 wk may be required to confirm the need for reoperating
because of continued partial improvement in cortisol levels after
the initial surgery.
Radiotherapy
Fractionated external beam radiotherapy or stereotactic ra-
diosurgery achieves control of hypercortisolemia in approxi-
mately 50–60%ofpatientswithin3–5yr (22, 33–36). It remains
to be determined whether stereotactic radiosurgery will result in
more rapidbiochemical control than conventional radiation (35,
37, 38). Long-term follow-up is necessary to detect relapse,
which can occur after an initial response to both types of
radiotherapy.
The incidence of therapy-induced pituitary failure appears to
be similarwith radiotherapy or radiosurgery. Insufficient studies
are available to evaluate the effects of radiotherapy on cerebro-
vascular and neurocognitive functions. The risk of second tumor
formation after pituitary radiation is considered to be in the
range of 1–2% (39), but this may not be due to the radiotherapy
per se.
Bilateral adrenalectomy
Bilateral adrenalectomy is adefinitive treatment thatprovides
immediate control of hypercortisolism. Furthermore, employing
minimally invasive adrenalectomydecreases the immediatemor-
bidity of this procedure (40–43). However, the resultant per-
manent hypoadrenalism requires careful education and evalua-
tion of patients because of the need for lifelong glucocorticoid
and mineralocorticoid replacement therapy. Performing regular
pituitary-directed MRI scans and evaluation of plasma ACTH
levels is mandatory in these patients to ascertainwhether there is
corticotroph tumorprogressionbecause of the risk of developing
Nelson’s syndrome (22, 44, 45).
The final treatment recommendation may in part depend on
the treatment options available, aswell as the acceptability of the
relative risks. Both repeat transsphenoidal surgery and radiation
therapy carry significant risks of hypopituitarism; the advantage
of surgery is that, if successful, the response is immediate. Ra-
diation therapy can eliminate tumors invading the dura or cav-
ernous sinus, both of which are frequent causes of surgical fail-
ure, which repeat surgery cannot do. Adrenalectomy is generally
amoremorbid procedure than either transsphenoidal surgery or
radiation therapy, carries the risk of Nelson’s syndrome, and
requires lifelong glucocorticoid and mineralocorticoid replace-
ment therapy. Nonetheless, the response is immediate and the
morbidity can be minimized by the use of endoscopic ap-
proaches. In general, we favor repeat transsphenoidal surgery as
the initial therapy for persistent or recurrent disease, with ra-
diosurgery or conventional radiotherapy if unsuccessful, but any
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treatment recommendation needs to be individualized. If remis-
sion is not achieved with reoperation, the choice between pitu-
itary-directed radiotherapyandbilateral adrenalectomy requires
consideration of pituitary status after pituitary surgery aswell as
the capacity of the patient to tolerate medical therapy while
awaiting the effects of radiotherapy. Bilateral adrenalectomy
may be indicated in patients with persistent hypercortisolism
despite treatment with adrenal enzyme inhibitors or with intol-
erance to these agents or as an alternative to long-term medical
treatment after pituitary radiotherapy and in women who wish
to maintain fertility without the need for ovulation induction.
Additional studies on the quality of life of patients treated
with either radiotherapy or bilateral adrenalectomy will be
important.
Part IV: Medical Therapy of Cushing’s Disease
Adrenal-directed therapy: steroidogenesis inhibitors
Adrenal-directed therapy (steroidogenesis inhibitors) may be
highly effectivebutdoesnot treat theunderlying tumoror restore
normal HPA secretory dynamics. Most experience with steroi-
dogenesis inhibitors has been acquired with metyrapone and
ketoconazole, which appear to be more effective and better tol-
erated than aminoglutethimide (46–55). Metyrapone treatment
leads to marked inhibition of aldosterone biosynthesis and ac-
cumulation of aldosterone precursors with weak mineralocor-
ticoid activity. Electrolyte balance and blood pressure levels vary
individually with the degree of aldosterone inhibition and 11-
deoxycorticosterone stimulation. Adverse effects due to in-
creased 11-deoxycorticosterone levels (hypokalemia, edema,
and hypertension) are infrequent (56). At present, metyrapone is
not commercially available in the United States, but it can be
provided for compassionate use by contacting the manufacturer
(Novartis) directly, whereas aminoglutethimide is no longer
available worldwide. Mild elevations in liver enzymes (up to
3-fold normal),which are transient, are not a contraindication to
medical therapy with ketoconazole, but liver function should be
monitored carefully because of the rare complication of liver
failure. The possibility of the development of hypogonadism in
men during ketoconazole therapy may favor the initial use of
metyrapone in this population. Conversely, the association of
hirsutism with metyrapone treatment in women may make ke-
toconazole a better choice in this population.
Interestingly, in contrast to subjects with an intact HPA axis,
patients with pituitary-dependent Cushing’s disease show no
compensatory rise, or decrease, in ACTH levels upon prolonged
administration of ketoconazole. According to human and ani-
mal studies, however, this phenomenon does not seem to involve
a direct effect onACTHsecretion but rather an adjustment in the
sensitivity of the HPA axis (47, 48, 50, 53, 54). Moreover, the
ACTH response to CRH in patients with Cushing’s disease was
enhanced (47) or unchanged (50) during ketoconazole treatment
comparedwith the pretreatment response. Taken together, these
findings argue against an additional site of inhibition at the pi-
tuitary level, although it was suggested by in vitro studies of
pituitary corticotrophs (57).
Mitotane (o,p’-DDD) may prove highly effective in the long-
term suppression of hypercortisolism in the majority of patients
with ACTH-dependent Cushing’s syndrome because of its spe-
cific adrenolytic action. Itsmechanismof actionalsoprevents the
risk of escape phenomenon in response to the ACTH rise that
occurs in Cushing’s disease when plasma cortisol is decreased
(58).However, its onset of action is slow (weeks ormonths), and
the adverse effects associated with mitotane therapy (mainly di-
gestive and neurological) require careful monitoring of drug lev-
els, and it is routinely used in only a few centers.
In situations where rapid control of cortisol levels is required
and oral therapy is problematic, iv etomidate therapy may be
considered (59–61).
Treatment with the glucocorticoid receptor antagonist mife-
pristone (RU486) has been reported in fewer than 20 patients
with ectopic ACTH secretion, and its use for this indication is
currently investigational (62). There is no significant experience
reported yet with this agent in patients with Cushing’s disease,
and assessment of its efficacy in the absence of a biochemical
marker is challenging.
The initial dose and escalation of the drugs used (Table 1)
depend on the severity of the presenting symptoms and biochem-
ical features. There are regional differences in regulatory ap-
provals; local prescribing information should be consulted.
Follow-up evaluations should include the examination of
clinical features and 24-h UFC levels, aiming for normalization
of both. A few centers use a cortisol day curve with five mea-
surements of serumcortisol over 12h,with a goal ofmaintaining
the mean level within normal limits. Blood samples are taken at
0900, 1200, 1500, 1800, and 2100 h, and the mean cortisol
levels are calculated; previous studies using an isotopic dilution
production rate technique have established that a mean level of
150–300 nmol/liter (5–10 g/dl) is equivalent to a normal
production rate (63). Several assessments may be advisable, be-
cause control may be variable with cyclical disease.
TABLE 1. Dosages of steroidogenesis inhibitors used in patients with Cushing’s disease
Drug Initial dosage
Maximal
dosage
Total daily
dose
Ketoconazole 200 mg bid 400 mg tid 1200 mg
Metyrapone 250 mg qid 1500 mg qid 6000 mg
Mitotane 500 mg tid 3000 mg tid 9000 mg
Etomidate Bolus of 0.03 mg/kg iv followed by
infusion 0.1 mg/kgh
0.3 mg/kgh
These recommendations are from the international consensus panel. Local prescribing information should be consulted because of regional differences in regulatory
approvals. bid, Twice daily; qid, four times daily; tid, three times daily.
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The choice of UFC assay should be considered carefully, with
tandem mass spectrometry considered most specific, and it is
important to note that normal ranges vary greatly depending on
the assaymethod. Although salivary cortisol measurementsmay
be an important endpoint in establishing efficacy and restoration
of normal cortisol levels, validation data in patients treated for
Cushing’s disease are needed. Whichever technique is used, the
aim is to restore a 24-h production rate of cortisol within the
normal range, although circadian rhythmicity may not neces-
sarily be restored. However, the clinical impact of these abnor-
mal rhythms remains unclear.
Adrenal-directed medical therapy is effective in the majority
of patients in a dose-dependent manner. Its indications might
include the preoperative preparation of patients to correct severe
complications of the disease quickly. In this context, the possi-
bility of avoiding hypoadrenalism immediately after surgery by
normalization of cortisol production for a sufficient length of
time preoperatively pertains to clinical observation rather than
randomized clinical trials and should be better explored. Drug
control of hypercortisolism is also suitable for patients awaiting
a response to radiation therapy and whenever a palliative treat-
ment is needed. In general, definitive therapy, either surgery or
radiotherapy, should be considered for all patients, and long-
term medical therapy alone is rarely indicated.
Tumor-directed medical therapy
Pituitary-directed therapy targets the underlying cause of the
disease, and therefore, several investigational agents are under
evaluation. Despite initial promise (54, 64–66), subsequent
studies do not support a routine clinical role for the use of per-
oxisome proliferator-activated receptor- (PPAR-) agonists,
such as rosiglitazone and pioglitazone (67–70). Although reti-
noic acid is effective at reducing ACTH in animal models (71)
and in dogs with Cushing’s disease (72), the effective dose used
is highandhumanclinical trial results arenot currently available.
Currentmedical therapies targeted to the corticotroph tumor
itself have not been uniformly successful. However, a medical
therapy that acts directly on the pituitary tumor to normalize
ACTH secretion and inhibit tumor growth would represent a
major nonsurgical advance in the treatment of this disease. Mo-
lecular studies provide a rationale for the use of somatostatin
receptor ligands for the treatment of corticotroph adenomas,
because these tumors express somatostatin receptor subtypes
sst1, sst2, and sst5, although expression of sst5 predominates (73,
74).The commercially available somatostatinanalogsoctreotide
and lanreotide are predominantly sst2-selective ligands and are
mostly ineffective in treating Cushing’s disease (75–77). Soma-
tostatin analogs with a broader somatostatin receptor subtype
affinity might be more effective. Pasireotide (SOM230; Novar-
tis, Basel, Switzerland), which has high affinity for sst1–3 and
especially sst5, shows promise as a tumor-directed medical ther-
apy in patientswithCushing’s disease (74, 78–81). Longer-term
trials are needed to determine the safety and efficacy of
pasireotide.
The dopamine D2 receptor is expressed in more than 75% of
corticotroph pituitary adenomas (82). In long-term studies with
bromocriptine, disease remission was confirmed in only a small
minority of patients (83). A small, short-term study suggests that
cabergoline at dosages of 2–3.5 mg/wkmay be effective in treat-
ing a subset of patients with Cushing’s disease (82). However,
more data are required not only for efficacy but also to address
the long-term safety of cabergoline in these patients (84, 85). The
use of combination pituitary-directed drug therapy (e.g. a do-
pamine D2 receptor agonist plus a sst receptor ligand) is an ex-
citing concept that has not been evaluated to date.
Previous studies have shown that serotonin antagonists and
-aminobutyric acid (GABA) agonists are generally ineffective
and are not routinely recommended (86).
Part V: Management of Ectopic ACTH
Syndrome, Nelson’s Syndrome, Special Patient
Populations, and the Patient after Successful
Surgical Treatment
Ectopic ACTH syndrome
Ectopic ACTH syndrome is a heterogeneous disease. Ectopic
ACTH-secreting tumors include small-cell lung cancer, thymic,
pulmonary, appendiceal, and pancreatic carcinoid tumors, gas-
trinomas pheochromocytomas, medullary thyroid cancer, and
other neuroendocrine tumors (87–89). The choice of treatment
for ectopic ACTH syndrome depends on tumor identification,
localization, and classification. Themost effective treatment op-
tion is surgical resection and cure, although this is not always
possible, e.g. inmetastatic disease or in the case of occult tumors.
Tumor-directed therapy involves a multidisciplinary, indi-
vidualized approach and can include somatostatin analogs, sys-
temic chemotherapy, interferon-, chemoembolization, radio-
frequency ablation, and radiation therapy (88–91). Adrenal-
directed therapy, i.e. medical therapy to block cortisol
production or bilateral adrenalectomy, is warranted in patients
with ectopic ACTH syndrome who have failed primary surgical
therapy. It is also used in patients with occult ectopic ACTH
syndrome or patients with malignant disease with metastases or
very severe symptoms of Cushing’s syndrome (92, 93).
Although some ectopic ACTH-producing tumors, such as
carcinoid tumors, may be indolent, others may be rapidly pro-
gressive, in which case prompt control of the hypercortisolemia
and related biochemical dysfunction, especially hypokalemia,
using an aggressive treatment regimen is important. Potassium-
sparing diuretics are valuable and, in extremis, iv etomidate can
be very useful (59, 94).
Nelson’s syndrome
Nelson’s syndrome comprises growth of a pituitary cortico-
troph adenoma after bilateral adrenalectomy and is associated
with symptoms due to physical compression of neurological
structures and increasedACTHsecretion.Reported rates ofNel-
son’s syndrome range from 8–29% (45). Rather than wait for
the development of Nelson’s syndrome after bilateral adrenal-
ectomy, close monitoring by regular MRI scans and plasma
ACTH levels should be undertaken to detect the occurrence of
corticotroph tumor progression. Pituitary MRI and ACTH
plasma level measurements are advised 3–6 months after bilat-
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eral adrenalectomy and then at regular intervals thereafter.
There is no validated predictive factor for Nelson’s syndrome
before surgery; however, a high plasma ACTH level (1000
ng/liter) in the year after bilateral adrenalectomy may be a pre-
dictive factor for corticotroph tumor progression (45).
The early detection of corticotroph tumor progression offers
the possibility of cure by surgery, particularly with microadeno-
mas. Alternatively, an invasive adenoma might require radio-
therapy, especially when repeated imaging shows a tumor pro-
gression. Fractionated external beam radiotherapy or
stereotactic radiosurgery can be used depending on tumor size
and location. Routine preventive radiotherapy after bilateral ad-
renalectomy is not generally warranted, and there is no proven
efficacious medical treatment for corticotroph tumor progres-
sion after bilateral adrenalectomy.
Pediatric/adolescent Cushing’s syndrome
The etiology of pediatricCushing’s syndrome varieswith age.
Adrenal hyperplasia secondary to McCune-Albright syndrome
tends tooccur in infants (meanage1.2yr), adrenocortical tumors
are found in young children (mean age 4.5 yr), and ectopic
ACTH syndrome is seen, albeit rarely, in older children (mean
age 10.1 yr). By contrast, primary pigmented nodular adreno-
cortical disease (mean age 13.0 yr) and Cushing’s disease (mean
age 14.1 yr) are most often seen in adolescents (95).
Transsphenoidal surgery by an experienced surgeon is the
preferred primary therapy of pediatric Cushing’s disease, with
cure rates similar to those seen in adult patients (96). If surgery
is unsuccessful, radiotherapy may be more effective than it is in
adult patients, with effective cure often occurring within 1 yr
(97). There is disagreement as to the utility of bilateral petrosal
sinus sampling in this age group to locate the tumor. However,
it is agreed that MRI is less useful in children than in adults,
because the tumor is often not visualized.
Many pediatric patients will have persistent GH deficiency
after successful transsphenoidal surgery (98, 99). It is important
to treat GH deficiency aggressively with GH replacement ther-
apy and to avoid supraphysiological glucocorticoid doses to
achieve the patient’s adult height potential. Early diagnosis and
treatment of GH deficiency is recommended to achieve optimal
long-term growth (100). In addition, although normalization of
decreasedbonemineral density generally occurs in the long term,
other metabolic abnormalities, particularly obesity, may remain
problematic (100).
Pregnancy and Cushing’s syndrome
Cushing’s syndrome in pregnancy occurs rarely but has a
significant effect on maternal and fetal morbidity. Detection of
Cushing’s syndrome usually occurs late in gestation, and the
diagnosis is complicated by the signs of normal pregnancy, such
as central weight gain, facial plethora, and pigmentation (101)
and the normal physiological changes in the maternal HPA axis.
The etiology of Cushing’s disease in pregnant patients varies.
Pituitary-dependent Cushing’s syndrome occurs in 33% of pa-
tients compared with 58–70% in nonpregnant groups. Adrenal
causes account for 40–50% of pregnant patients (adrenal ade-
noma 46%, adrenal carcinoma 10%) compared with 15% in
nonpregnant groups. ACTH-independent adrenal hyperplasia is
seen in 3%of patients and ectopic Cushing’s syndrome in 3%of
patients (102, 103). Recurrent ACTH-dependent Cushing’s syn-
drome during pregnancy has been describedwith the presence of
LH/human chorionic gonadotropin receptors in the adrenal cor-
tex (104).Maternalmorbidity includeshypertension (68%), glu-
cose intolerance (25%), and preeclampsia (14%), whereas fetal
morbidity includes prematurity (43%), intrauterine growth re-
striction (21%), and stillbirth (6%) (102).
The treatment of choice for Cushing’s disease in pregnancy is
pituitary surgery, which should be undertaken as soon as pos-
sible or before the late third trimester. Although bilateral adre-
nalectomy is technically possible during gestation for patients
with tumor remnant after transsphenoidal pituitary surgery, it is
best reserved until the postpartum period. Second-line therapy
with steroidogenesis inhibitors carries apotential risk to the fetus
due to adverse effects from the medications. As a result, regula-
tory authorities in the United States and Europe consider keto-
conazole,metyrapone, andmitotane either tobe contraindicated
in pregnancy or indicated only if the risk to the fetus is out-
weighed by the risks of nontreatment. If treatment is considered,
metyrapone is recommended rather than ketoconazole, because
of its effects of inhibition of androgen inhibition. It is also rec-
ommended overmitotane, because of its potential teratogenicity
(105–107).
Postoperative treatment of secondary adrenal
insufficiency
As noted above, successful surgery unmasks secondary adre-
nal insufficiency, so that nearly all patients require glucocorti-
coid replacement therapy. During the first postoperative year,
the HPA axis recovers in most patients, allowing for discontin-
uation of these medications (all patients require glucocorticoid
and mineralocorticoid replacement therapy after bilateral adre-
nalectomy, and this is not considered further here).
Ideally, the dosage of glucocorticoids after surgery should be
equivalent to replacement dosages, e.g. hydrocortisone 12–15
mg/m2 (or an equivalent) in a single morning dose or a divided
dose with the majority given in the morning. This dosage avoids
the continued suppression of theHPA axis and the prolongation
of Cushingoid features associated with higher dosages. How-
ever, some patients have prominent features of glucocorticoid
withdrawal that overlap with classical symptoms of adrenal in-
sufficiency. These features include fatigue, depression, joint
aches, nausea, and anorexia. If possible, we suggest that these
patients receivehydrocortisone replacement therapyat theupper
end of normal (i.e. 15 mg/m2) in a split-dose regimen and be
encouraged that these symptoms will improve in the first post-
operative month. If the symptoms are intolerable, the glucocor-
ticoid dose may be raised slightly above replacement, but sup-
raphysiological doses should be tapered to replacement doses as
soon as possible, ideally within the first month after surgery.
Replacement therapy can be stopped when the morning cortisol
level or the cortisol response to cosyntropin (Cortrosyn) is
greater than 18 g/dl (500 nmol/liter).
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Conclusions
ACTH-dependent Cushing’s syndrome is a heterogeneous dis-
order and requires a multidisciplinary and individualized ap-
proach to patient management. In general, the treatment of
choice forACTH-dependentCushing’s syndrome is curative sur-
gery with selective pituitary or ectopic corticotroph tumor re-
section, although this is not always possible. Second-line treat-
ments include more radical surgery, radiation therapy (for
Cushing’s disease), medical therapy, and bilateral adrenalec-
tomy. Because of the significant morbidity of Cushing’s syn-
drome, early diagnosis and prompt therapy are warranted.
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